Investment Climate

Episode 76: Proba: Sijbrand Tieleman on raising an Extension Round and dominating a hyper-niche market 
In this episode, I sit down with Sijbrand Tieleman, Co-founder and CEO of Proba, an Amsterdam-based startup tackling the massive footprint of fertilizer emissions. Sijbrand walks us through his recent €1.25M ($1.5M USD) extension round, which was led by existing investor Future Food Fund. We discuss the strategic decision to raise from the current cap table rather than burning time chasing new investors, the reality of setting achievable milestones, and why agriculture startups cannot be measured by traditional SaaS ARR metrics. Most importantly, Sijbrand delivers a masterclass on finding a competitive moat by becoming the absolute world leader in a highly specific, hyper-niche use case before expanding into larger markets. 
🎧 Listen to the full episode to hear how Sijbrand navigated the delicate valuation negotiations with his existing investors to secure 18-24 months of runway.
Key Facts Proba:
Goal: To help the agri-food supply chain quantify and reduce greenhouse gas emissions specifically related to fertilizer use.
Milestone: Recently closed a €1.25M extension round, primarily funded by their existing investors, to focus entirely on business execution without the distraction of a protracted fundraising roadshow.
Alex’s Top Findings: 
The Power of the Hyper-Niche. Startups often fail by trying to solve too many problems across too many industries. Proba initially explored steel and cement before pivoting entirely to fertilizer emissions. Sijbrand explains that by picking a "vertical within a vertical," Proba created a monopoly. They didn't just target agriculture; they targeted the specific emissions effect of nitrification inhibitors used alongside urea fertilizer for coffee grown in the Minas Gerais region of Brazil. "The more opportunity you give yourself to become successful, that I think is kind of a lesson... just make it super small and then extend from there... You want to position yourself in a way that there's no competition. If somebody wants to solve the problem, they more or less need to come to you."
The "Insider" Extension Round. Instead of spending 8 months pitching 100 new VCs, Proba chose to raise an extension round directly from their current investors. Sijbrand reveals that they began discussing the need for this follow-on capital just two months after closing the previous round. By maintaining transparent communication and setting realistic milestones, they secured the cash needed to focus on the business rather than the roadshow. "We kind of took a bit of an implicit decision to say... we can go out there to the capital market and basically spend a lot of time finding a new investor without guarantee on success, or we spent a bit less time together with the existing investors and basically have more time to spend in the actual business."
Agriculture SaaS is Not Silicon Valley SaaS. Sijbrand highlights a critical disconnect between generalist VCs and AgTech startups. Generalist funds demand rapid Month-over-Month Monthly Recurring Revenue (MRR) growth. However, agriculture operates on physical, annual growing seasons. Proba partnered with specialized investors (Future Food Fund) who understand that growth in this sector is a compounding, season-by-season process, not an overnight software rocket ship. "Building a business in agriculture has a bit of a different speed... things need to grow in a physical world and they grow in one growing season... The normal SaaS investors who are used to [rapid] ARR levels are not interested yet.”

Episode 75: ID Capital: Isabelle Decitre on the "Anti-Fund" model and the harsh realities of expanding into Asia 
In this episode, I sit down with Isabelle Decitre, founder of ID Capital, a Singapore-headquartered venture investment and innovation advisory firm. Isabelle reveals why she deliberately chose not to raise a traditional VC fund, opting instead to invest her own capital (writing tag-along Series A checks up to $1M) to maintain flexibility and leverage deep "ecosystem intelligence." We discuss the brutal truth about expanding into Asian markets, why startups need to stop using "China is big" as a business plan, and how Australian startup AllG successfully pivoted from complex casein micelles to high-margin Lactoferrin to de-risk their commercialization. Finally, Isabelle throws down a spicy challenge to the industry, questioning if the Silicon Valley "Power Law" actually works in AgriFoodTech. 
🎧 Listen to the full episode to hear Isabelle’s unfiltered thoughts on funds that rely on a single lucky exit to show returns.
Key Facts ID Capital:
Goal: To invest in and advise Series A AgriFoodTech startups through a climate lens, focusing heavily on adjacent sectors like circularity and biomanufacturing.
Milestone: Rebranding their flagship 10-year annual conference from "Future Food Asia" to "Future Fit Asia," reflecting a shift beyond just food matrices into the interconnectedness of soil and human health.

Alex’s Top Findings:
The "Anti-Fund" Ecosystem Model. Isabelle doesn't manage LP money; she invests from her own balance sheet. She argues that the traditional VC mold forces GPs to promise 20%+ IRRs that often aren't realistic in FoodTech. By remaining independent, ID Capital operates as a "one-stop shop" offering startups optionality: if a direct investment isn't the right fit, she can leverage her advisory arm to facilitate introductions to massive strategic corporate clients or showcase the tech at her conference. "We are not a fund... I'm investing my own money. We don't have any LP... I didn't see myself promising 20% plus IRR on a time period of six years... The way I wanted to see myself as a significant player was not just by being defined by my check size, but being defined by whom I could influence and bring around the table."
The Asia Expansion Reality Check: Stay in Your Habitat. Startups frequently pitch Asia expansion based solely on the region's massive population. Isabelle warns that entering Asia is a massive cost center long before it generates revenue. If a startup is thinly funded, her advice is blunt: stay home. You must have dedicated capital and a localized strategy, not just "wishful dreaming." "The best advice I can give you is just to remain in your natural habitat and ecosystem and don't waste your money traveling to China or Asia every other day. It will cost you a bomb... What looks good is when people start to have the awareness that developing Asia would be a cost first before it's a source of revenue."
Pivoting to High-Margin Optionality (The AllG Playbook). Investors today want startups to be as de-risked as possible. Isabelle highlights her investment in AllG to show what good pivoting looks like. Even though they had world-class expertise in precision fermentation for casein micelles, they didn't stubbornly stick to that narrative. They aggressively pivoted to a higher-value, faster-to-commercialize compound (Lactoferrin) and leaned into the Chinese market. "They didn't stay fixated on one application or one narrative. Although they were really very, very proficient in casein micelles... they thought very smartly of pivoting toward higher value compounds... It is really about not being wedded to your own science and your own narrative."

Send a text
On unlocking Canada’s $7B AgTech boom and solving the scale-up "Valley of Death" - Mike Wolsfeld, AgWest Bio
Investment Climate Podcast: Fundraising Playbooks From Food Tech CEOs and VCs 
In this podcast series, Alex Shandrovsky interviews investors about benchmarks for funding Alt Proteins in 2025 and uncovers the investment playbooks of successful Climate Tech CEOs and Leading VCs.
Podcast Host Alex Shandrovksy is a strategic advisor to numerous global food tech accelerators and companies, including alternative proteins and cellular agriculture leaders. His focus is on investor relations and post-raise scale for agrifood tech companies. This podcast is syndicated through our media partners, Foodtech Weekly and Vegconomist.
Episode 74: AgWest Bio: Mike Wolsfeld on unlocking Canada’s $7B AgTech boom and solving the scale-up "Valley of Death" 
In this episode, I sit down with Mike Wolsfeld, who manages the Techcom Fund at AgWest Bio. Operating as an equity investment fund ($50k–$300k checks) embedded inside a non-profit, Mike shares how they are turning Saskatchewan into a global magnet for precision fermentation and ag-tech startups. We discuss their unique mandate: attracting international deep-tech companies (like Argentina's Ergo) to the Canadian Prairies without forcing them to move their headquarters. Mike breaks down how their GAAP (Global Agri-Food Advancement Partnership) facility bridges the critical scale-up gap between bench science and commercial co-manufacturing, and why Canada’s crown corporations, like Farm Credit Canada (FCC), are deploying a historic $7 billion into the sector despite a broader VC downturn. 
🎧 Listen to the full episode to hear Mike’s advice on how foreign startups can tap into Canada's massive pools of non-dilutive capital.
Key Facts AgWest Bio:
Goal: To invest in and support early-stage ag-tech and food-tech companies by leveraging Saskatchewan's deep agricultural history, biotech talent pool, and specialized infrastructure.
Milestone: Actively deploying a $7M evergreen fund while scaling the GAAP facility to help international precision fermentation companies seamlessly enter the Canadian ecosystem.
Alex’s Top Findings:
The "Gateway to Canada" Geo-Arbitrage. AgWest Bio offers a highly founder-friendly entry into the Canadian ecosystem. Unlike many regional funds that demand a full headquarters relocation, Mike’s fund only requires a federally incorporated subsidiary and 1-2 local employees. This allows international founders to access Canada's massive non-dilutive grants and specialized infrastructure without disrupting their global cap tables. "We're not asking for companies to entirely reincorporate, move everything here, move families... really, at minimum, what it looks like is a federally incorporated company with at least one or two full-time employees here in the province... I'm not interested in forcing companies to move here; I'm interested in supporting companies in their existing strategy."
Bridging the Fermentation "Valley of Death". The hardest part of precision fermentation isn't the lab science; it's scaling from milliliters to commercial thousands of liters. AgWest Bio manages the GAAP facility to explicitly solve this missing middle step, providing heavily discounted, shared-use bioreactors (5L to 100L) to get startups ready for large-scale co-manufacturing. "We're really trying to fill what we saw as a gap between that lab scale, bench scale, and scale up... taking things out of an academic sort of research stage into that pre-commercialization... proving that it can scale up from milliliters to liters to 10 liters to sort of 20, 50."
The $7 Billion Crown Corporation Lifeline. While traditional VC fundrais

Send a text
Episode 73: CJ Foods: Auroni Majumdar on the Open Innovation Playbook and bypassing the Western retail trap 
In this episode, I sit down with Auroni Majumdar, Vice President of R&D Global Open Innovation at CJ Foods. Auroni pulls back the curtain on how a global food giant evaluates external technology, revealing why it operates on a strict 6-to-24-month horizon rather than chasing 10-year moonshots. We discuss the eight core product categories CJ cares about, why a startup's regulatory and shelf-life readiness is non-negotiable, and how startups can bypass the grueling 3-year Western retail reset cycle by leveraging CJ's vertical integration in Asian markets. Finally, Auroni outlines a highly unique "Triangle Partnership" where CJ’s Bio division provides the fermentation scale-up capacity while the Foods division acts as the guaranteed offtake customer. 
🎧 Listen to the full episode to hear Auroni’s advice on how to build an internal champion and why pitching technology without doing your homework on their current unit economics is a major red flag.
Key Facts CJ Foods:
Goal: To source mature, externally developed technologies (ingredients, process, packaging) to drive immediate growth across 8 global strategic categories (including dumplings, Korean fried chicken, kimchi, and sauces).
Milestone: Successfully integrated 6 distinct technology adoptions (including sweeteners, sensors, and solid-state fermentation capabilities) within the last calendar year.
Alex’s Top Findings:
The "Near-Term" Mandate: No Science Projects. Auroni is exceptionally clear: CJ Foods is in the business of using technology, not commercializing raw academic research. If your tech is 3-4 years away from regulatory approval or commercial scale, it is too early for their core pipeline. They prioritize solutions with proven unit economics, and that can hit the market within 6 to 24 months. "I want to do what we do well, or CJ does well, right? What we do well is we launch products fast on a global basis... I don't want to spend money doing research projects. That's not what I do. That's not my business model... I'm a great user. I'm a great evaluator."
Bypassing the Western Retail Trap. Startups often get mesmerized by the idea of landing a massive Western FMCG contract, ignoring that nationwide US distribution—dictated by rigid big-box retailer shelf resets and mandatory shelf-life studies—can take over 3 years to execute. Auroni highlights that CJ offers a faster, more nimble alternative through its vertical integration and the inherently quicker innovation cycles of Asian markets. "In the US, nationwide distribution requires your big box retailers... inherently, if you're a startup that's working in this system... you're already at three years in this system... CJ in Korea can move extremely fast. We're very vertically integrated... it might not be as big as [a Western MNC], but it'll be big and meaningful, and it'll be quicker."
The CJ "Triangle" of Scale: Foods + Bio + Startup. One of the most unique advantages CJ offers precision fermentation startups is its internal structure. CJ can facilitate a three-way partnership: the startup provides the IP, the CJ Bio Foundry provides the heavy CapEx fermentation scale-up, and the CJ Foods division acts as the built-in, guaranteed offtake customer. "Where there's offtake demand from the food side, where there's a technology provider that needs scale-up capability... and then there's a business [CJ Bio] that has fermentation capability and connecting that triangle in a way that there's mutual benefit across the three parties."

Send a text
Harmony Baby Nutrition: Del Afonso shares how to get funded in 2026
Investment Climate Podcast: Fundraising Playbooks From Food Tech CEOs and VCs 
In this podcast series, Alex Shandrovsky interviews investors about benchmarks for funding Alt Proteins in 2025 and uncovers the investment playbooks of successful Climate Tech CEOs and Leading VCs.
Podcast Host Alex Shandrovksy is a strategic advisor to numerous global food tech accelerators and companies, including alternative proteins and cellular agriculture leaders. His focus is on investor relations and post-raise scale for agrifood tech companies. This podcast is syndicated through our media partners, Foodtech Weekly and Vegconomist.
Episode 72: Harmony Baby Nutrition: Del Afonso on Geo-Arbitrage, securing a $6M Brazilian grant, and bypassing the infant formula cartel 
In this episode, I sit down with Del Afonso, Founder and CEO of Harmony Baby Nutrition. Del shares his masterclass on "geo-arbitrage"—how he bypassed the exorbitant costs of the Boston biotech bubble by setting up formulation labs in Brazil and analytical labs in Hong Kong, stretching his 18-month runway significantly. We dive into how his team successfully secured a massive $6M non-dilutive grant from the Brazilian Development Agency to build a local manufacturing and R&D hub. Del also explains his bold pivot away from the endless R&D cycle to commercialize their "Generation 1" product via a Direct-to-Consumer (D2C) brand, rather than falling into the B2B ingredient trap with legacy corporations.
🎧 Listen to the full episode to hear why powdered formula is fundamentally flawed and how Harmony is raising a $2M bridge round to bring a sterile, liquid alternative to the market.
Key Facts Harmony Baby Nutrition:
Goal: To revolutionize the $100B infant nutrition industry by creating a sterile, human-breastmilk-based liquid formula that supports gut microbiome health without industrially added sugars.
Milestone: Secured a $6M grant from the Brazilian Development Agency to build an R&D and manufacturing center, and is currently raising a $2M convertible note to drive the commercial launch of their Gen 1 product in the US.
Alex’s Top Findings:
The Geo-Arbitrage Playbook: Extending Runway with Global R&D. Operating a biotech startup in Cambridge, MA, is prohibitively expensive. Del’s solution was to keep the HQ in the US but offshore the heavy scientific lifting. By utilizing highly qualified PhDs in Brazil and leveraging 70% wage reimbursement programs in Hong Kong, Harmony drastically cut their burn rate. "We grew up on scarcity. Big time... The amount of money we were paying for a senior researcher in the US, we can hire four to five researchers in Brazil. So it's unbelievable the difference... It's a strategic way that we can balance a bit of the high cost of doing science within the Boston area."
Drawing the Line on the "Endless" R&D Cycle. Many deep-tech founders get stuck in the lab perfecting their technology while their runway evaporates. Del realized that to survive the current fundraising winter, they had to draw a hard line in the sand, freeze the "Generation 1" formula, and pivot entirely to commercialization to prove revenue traction before attempting a Series A. "Doing R&D could be like an endless process. And how do you actually get a point, okay, we have enough... I got all the researchers... to say listen, this is the deadline for this... If not, we're gonna turn on the key, we're gonna do only the commercial work."
Value Capture Requires a B2C Brand, Not a B2B Partnership. While selling a patented ingredient to a giant like Nestlé seems like the easier path, it leaves the startup with zero bargaining power. Del emphasizes that in mon